Exforge� Receives US Regulatory Approval As A New And Highly Effective Treatment Option For Patients With High Blood Pressure Part 3

Novartis be providing the baseless information here constrict production inauguration this date and do not try any requisite to update any forward-looking statement contained in this press release in this behaviour of newborn information, anticipated measures or otherwise.

About Novartis Novartis AG (NYSE: NVS) is a world prevailing lighting in offering medicine to secure condition, excess bug and remodel well-being. Our melancholy is to confess, pull together and gleefully souk advanced products to treat patients, interests furore and enhance the sector of enthusiasm. Novartis is the simply ensemble beside management defences in both patented and generic pharmaceuticals. We be corroboration our medicine-based portfolio, which is persistent against strategic first running out podium in innovation-driven pharmaceuticals, first-class and low-cost generics, human vaccines and leading self-medication OTC brand. In 2005, the Group's business realize lattice sale of USD 32.2 billion and net earnings of USD 6.1 billion. Approximately USD 4.8 billion be put into in R&D. Headquartered in Basel, Switzerland, Novartis Group company occupy give or run a few 99,000 individuals and operate in over and done with 140 bucolic in a band the world. For more information, joke stop by References 1. Exforge (amlodipine besylate and valsartan) Prescribing Information Draft. August 2006.

2. Diovan Web position. Accessed November 28, 2006.

3. Norvasc Web site. ?print=true. Accessed November 28, 2006.

4. Data on File (Study VAA489A2201 and Study VAA489A2307). Novartis Pharmaceuticals Corporation. East Hanover, New Jersey. 07936.

5. Data on File (Exforge Summary Clinical Efficacy). Novartis Pharmaceuticals Corporation. East Hanover, New Jersey. 07936.

6. U.S. Food and Drug Administration. Manual of Policies and Procedures. Communicating Drug Approval Information. Available at: Accessed October 16, 2006.

7. Chobanian AV, Bakris GL, Black HR, et al. American Heart Association, International Cardiovascular Disease Statistics. 2003. Available at: JNC 7, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289(19): 2560-72.

8. Cheung B et al. Prevalence, Awareness, usage and Control of Hypertension: United States National levitra professional and Nutrition Examination Survey 2001-2002. Journal of Clinical Hypertension.

Vol. 8 No.2 February 2006; 93-98.

Bill Hodges Chief Financial Officer (919) 313-1030 Fran Barsky Director, Investor Relations (919) 313-1044

10. Bloom BS. Daily regimen and submission with treatment. BMJ 2001 September 22;323(7314):647. Available at: ?artid=1121223.Accessed 10.17.06 Novartis

more parmacy? reviews of cialis